Morgan Stanley Kala Pharmaceuticals, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.25 - $0.36 $5,068 - $7,298	-20,273 Reduced 16.41%	103,292 $23,000
Q2 2022 Oct 27, 2022	SELL	$0.3 - $1.31 $8,743 - $38,181	-29,146 Reduced 19.09%	123,565 $37,000
Q2 2022 Aug 15, 2022	SELL	$0.3 - $1.31 $8,743 - $38,181	-29,146 Reduced 19.09%	123,565 $37,000
Q1 2022 Oct 27, 2022	BUY	$0.61 - $1.84 $17,779 - $53,628	29,146 Added 23.59%	152,711 $210,000
Q1 2022 May 13, 2022	SELL	$0.61 - $1.84 $37,376 - $112,742	-61,273 Reduced 28.63%	152,711 $210,000

Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.74 $107,180 - $253,167	-92,397 Reduced 30.16%	213,984 $260,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $5.43 $802,718 - $1.66 Million	306,381 New	306,381 $802,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $10.4M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.